Floatz logo

Osimertinib

Peripheral T Cell Lymphoma

Dizal PharmaceuticalsSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
73/ 100

Competitive context

52 Active assets in the Peripheral T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Tucidinostat
Ruijin Hospital
Phase 4BB
DEXAMETHASONE
Ou Bai, MD/PHD
Phase 4BB
Ifosfamide
New York Medical College
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Ou Bai, MD/PHD
Phase 4BB
Nivolumab
University of Michigan Rogel Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Osimertinib is also rated in:

EGFR Exon 19 DeletionDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →